Anaphylaxis Campaign

Supporting people at risk of severe allergies

DonateEMERGENCY INSTRUCTIONS

Explore our Website

Access our Knowledgebase
The Knowledgebase is an online resource where you can search for information about allergy.
Information for Newly Diagnosed
Around one third of the UK population (approximately 19 million people) will develop an allergy at some time in their lives.
Fundraise
From marathons to wigs, everyone can fundraise!
Events
Find out what's going on near you.
Membership
Join us as a member of the Anaphylaxis Campaign today and help us to raise the profile of severe allergy and support those who live with life threatening allergies.
AllergyWise
AllergyWise is our online e-learning website with a selection of courses for you to learn about anaphylaxis, the risks of severe allergies and how to manage them.

Topics of Interest

Managing Allergens in the Workplace

We have developed a comprehensive guide for employees and employers to help people with severe allergies at work, including an adult allergy action plan. Read more…

Support Group Events

Our Support Groups are organised by our friendly volunteers, and are the perfect chance to meet other people living with severe allergies in your local area. Read more…

Making Schools Safer

Every school is likely to have at least one pupil who is severely allergic to a type of food, and many schools will have more. Read more…

News

Does your child have peanut allergy?

8th January 2021

Have they taken part or are they taking part in a peanut protein powder clinical trial? Acaster Lloyd Consulting are looking for participants to take part in a research study about caregivers’ and children’s experiences of an oral peanut protein powder (immunotherapy) treatment. What does it involve? This study will involve completing an online survey […]

Read More...

European Commission approves first treatment for peanut allergy

7th January 2021

Aimmune Therapeutics’ PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy. The European Commission (EC) has approved PALFORZIA®  for the treatment of peanut allergy, making it the first treatment for the condition. Produced by Aimmune Therapeutics, a Nestlé Health Science Company, PALFORZIA is indicated in patients aged four to 17 […]

Read More...

Allergy Therapeutics and Imperial College London start Peanut Allergy Study

6th January 2021

Allergy Therapeutics PLC – Sussex-based biotechnology firm focused on allergy vaccines – Initiates peanut allergy biomarker study with Imperial College London to confirm potential of novel peanut vaccine candidate. The study aims to evaluate the novel virus like particle based peanut allergy vaccine candidate, to confirm its hypoallergic potential and its potent immune response. Submission […]

Read More...

Entrepreneur and allergy advocate Julianne Ponan is named Anaphylaxis Campaign’s newest ambassador

16th December 2020

The Anaphylaxis Campaign, the only UK-wide charity operating solely for the growing numbers of people at risk from severe allergic reactions, has welcomed a new Ambassador to help raise awareness and create a safer environment for those with allergies. Julianne Ponan, who is well known amongst the allergic community as a professional speaker and founder of […]

Read More...